In the CT26 model, exoASO-STAT6 treatment induced activation of tumor-infiltrating CD8 T cells, and the antitumor activity of exoASO-STAT6 was abrogated by CD8 T cell depletion. The gene discussed is STAT6; the disease is neoplasm.